A life-saving opioid overdose treatment could soon be as common as Tylenol on retail store shelves. The question is whether making it more accessible will get it to the people who need it the most.
Why it matters: Wednesday's FDA approval of Narcan for over-the-counter use has a financial cost. And if insurers or governments don't step up, addiction experts fear it could widen health disparities and undercut the FDA’s goals of addressing a "dire public health need."
